Evidence map›Paper›PMID 36394352›Full record

ArticleAmerican journal of reproductive immunology (New York, N.Y. : 1989)2023

Expression and T cell regulatory action of the PD-1 immune checkpoint in the ovary and fallopian tube.

Joshua Johnson, So-Youn Kim, Peter Ka Sam, Rengasamy Asokan, Evelyn Llerena Cari, Elise S Bales, Thanh-Ha Luu, Lauren Perez, Amanda N Kallen, Liesl Nel-Themaat and 5 more

Open access · greenAbstract read
In one paragraph

Article in American journal of reproductive immunology (New York, N.Y. : 1989), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 6 institutions in 1 country.

Joshua JohnsonDepartment of Obstetrics and Gynecology, Division of Reproductive Sciences, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.ORCID 0000-0002-6016-8089
So-Youn KimDepartment of Obstetrics and Gynecology, College of Medicine, Olson Center for Women's Health, University of Nebraska Medical Center, Omaha, Nebraska, USA.
Peter Ka SamUniversity of Colorado-Boulder, Boulder, Colorado, USA.
Rengasamy AsokanDepartment of Obstetrics and Gynecology, Division of Reproductive Sciences, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
Evelyn Llerena CariDepartment of Obstetrics and Gynecology, Division of Reproductive Sciences, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
Elise S BalesDepartment of Obstetrics and Gynecology, Division of Reproductive Sciences, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
Thanh-Ha LuuDepartment of Obstetrics and Gynecology, Division of Reproductive Sciences, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
Lauren PerezUniversity of California-Los Angeles, Los Angeles, California, USA.
Amanda N KallenYale School of Medicine, Department of Obstetrics, Gynecology & Reproductive Sciences, New Haven, Connecticut, USA.
Liesl Nel-ThemaatDepartment of Obstetrics and Gynecology, Division of Reproductive Endocrinology and Infertility, Aurora, Colorado, USA.
Alex J PolotskyDepartment of Obstetrics and Gynecology, Division of Reproductive Sciences, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
Miriam D PostDepartment of Pathology, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.ORCID 0000-0001-7220-8247
David J OrlickyDepartment of Pathology, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.ORCID 0000-0002-0417-1400
Kimberly R JordanDepartment of Immunology and Microbiology, Human Immunology and Immunotherapy Initiative, Human Immune Monitoring Shared Resource, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
Benjamin G BitlerDepartment of Obstetrics and Gynecology, Division of Reproductive Sciences, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
University of Colorado Anschutz Medical Campus · USColorado Center for Reproductive Medicine · USUniversity of California, Los Angeles · USUniversity of Colorado Boulder · USUniversity of Nebraska Medical Center · USYale University · US

Funding

University of Colorado Cancer Center Support Grant - Lung Cancer Patient-Derived Xenografts with Autologous Human Immune SystemsP30CA046934 · NCI · UNIVERSITY OF COLORADO DENVER · PI James V Degregori · 1988 to 2026
$117.0M
Targeting Wnt signaling in therapy-resistant ovarian cancerR37CA261987 · NCI · UNIVERSITY OF COLORADO DENVER · PI Benjamin G Bitler · 2021 to 2026
$2.4M
Targeting Wnt signaling to overcome PARP inhibitor resistance in ovarian cancerR00CA194318 · NCI · UNIVERSITY OF COLORADO DENVER · PI BITLER, BENJAMIN G · 2017 to 2019
$745k
NCI NIH HHS P30 CA046934NCI NIH HHS R00 CA194318NCI NIH HHS R37 CA261987
6 · The paper itself

Abstract

problemImmune cell trafficking and surveillance within the ovary and fallopian tube are thought to impact fertility and also tumorigenesis in those organs. However, little is known of how native cells of the ovary and fallopian tube interact with resident immune cells. Interaction of the Programmed Cell Death Protein-1 (PD-1/PDCD-1/CD279) checkpoint with PD-L1 is associated with downregulated immune response. We have begun to address the question of whether PD-1 ligand or its receptors (PD-L1/-L2) can regulate immune cell function in these tissues of the female reproductive tract. METHOD OF STUDY: PD-1 and ligand protein expression was evaluated in human ovary and fallopian tube specimens, the latter of which included stages of tubal cell transformation and early tumorigenesis. Ovarian expression analysis included the determination of the proteins in human follicular fluid (HFF) specimens collected during in vitro fertilization procedures. Finally, checkpoint bioactivity of HFF was determined by treatment of separately-isolated human T cells and the measurement of interferon gamma (IFNγ).

resultsWe show that membrane bound and soluble variants of PD-1 and ligands are expressed by permanent constituent cell types of the human ovary and fallopian tube, including granulosa cells and oocytes. PD-1 and soluble ligands were present in HFF at bioactive levels that control T cell PD-1 activation and IFNγ production; full-length checkpoint proteins were found to be highly enriched in HFF exosome fractions.

conclusionThe detection of PD-1 checkpoint proteins in the human ovary and fallopian tube suggests that the pathway is involved in immunomodulation during folliculogenesis, the window of ovulation, and subsequent egg and embryo immune-privilege. Immunomodulatory action of receptor and ligands in HFF exosomes is suggestive of an acute checkpoint role during ovulation. This is the first study in the role of PD-1 checkpoint proteins in human tubo-ovarian specimens and the first examination of its potential regulatory action in the contexts of normal and assisted reproduction.

Indexed as

Fallopian TubesOvaryProgrammed Cell Death 1 ReceptorB7-H1 AntigenCarcinogenesisFemaleHumansLigandsT-LymphocytesB7-H1 AntigenLigandsPDCD1 protein, humanProgrammed Cell Death 1 Receptorautoimmunityfallopian tubefertilityimmune checkpointsovarian cancerovaryPD-1 pathway

Identifiers

PMID36394352
PMCPMC10559227
OpenAlexW4309246226

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.